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Abstract Tumor necrosis factor-a (TNF-a), an adipoki-
ne, is produced in adipocytes, and the elevation of its levels
has been linked to obesity and insulin resistance in some
population. In this study the relationship between TNF-a
promoter gene polymorphism and obesity in an Iranian
population has been studied. Subjects were randomly
selected from Tehran Cohort Lipid and Glucose Study.
Adult participants placed in three groups according to their
body mass index (BMI): BMI \ 25, 25 B BMI \ 30,
BMI C 30 and under-18 subjects placed in two groups,
under 85th percentile BMI and above 85th percentile.
Finally, 244 persons were selected for G-308A and G-238A
polymorphisms analysis. The FBS, high-density lipopro-
tein cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), triglyceride, cholesterol levels and blood
pressure and HOMA of all subjects were measured. The
polymorphism -308 and -238 were revealed by restric-
tion fragment length polymorphism (RFLP; NCOI and
MSPI) after the promoter site was amplified by PCR. The
allele frequency of TNF-a polymorphism was in the
Hardy–Weinberg equilibrium. There was no relation
between BMI and the frequency of this allele. The fact that
there is no association between G-308A and G-238A TNF-
a promoter polymorphisms and obesity probably shows
that it is not an important risk factor for obesity and con-
sequently for cardiovascular disease.
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Introduction
There has been an increase of prevalence of obesity which is
associated with several adverse health problems, including
type 2 diabetes, hyperlipidemia and hypertension. The role
obesity plays in the development of obesity-related disorders
is complex and probably due to an interaction of genetic,
nutritional and metabolic factors [1, 2]. A number of can-
didate genes have been implicated in the pathogenesis of
obesity in humans. Tumor necrosis factor-a (TNF-a) is pri-
marily secreted in adipocytes, and elevated levels of this
cytokine have been linked to obesity and insulin resistance.
TNF-a messenger RNA levels in skeletal muscle and adipose
tissue of humans are positively correlated with body mass
index (BMI), fat mass, and insulinemia and inversely cor-
related with lipoprotein lipase activity [3–5]. The gene which
is coded human TNF-a is located on the short arm of chro-
mosome 6 [6]. Recently, attention has been focused on two
nucleotide polymorphisms identified in the promoter region
of the TNF-a gene: G ? A substitutions at -308 and -238
respectively. In vitro experiments have demonstrated that the
polymorphism -308 which is identified by NcoI restriction
fragment length polymorphism (RFLP), increases tran-
scriptional activation of the TNF-a gene [7]. The potential
functional impact of the polymorphism at position -238 of
the TNF-a gene has not yet been investigated in in vitro
expression studies. However, the variant is located within a
putative Y box, which is a regulatory motif typical of the
promoter region of major histocompatibility complex class II
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genes [8]. The purpose of the present study is to determine
whether the two mentioned TNF-a promoter polymorphisms
are associated with obesity in Iranian population.
Materials and methods
Subjects were randomly selected from Cohort Tehran
Lipid and Glucose Study and adults were classified in
three groups according to their BMI: BMI \ 25,
25 B BMI \ 30, BMI C 30. As for -308 polymorphism,
202 adults (81 men, 121 women) and 42 under-18 subjects
(21 boys, 21 girls) were placed in two groups according to
their BMI: under and above 85th percentile as far as age
and sex are concerned. And as for -238 polymorphism,
239 (78 men, 120 women) and 41 under-18 subjects
(17 boys, 24 girls) were classified in two groups according
to their BMI: under and above 85th percentile as far as age
and sex are concerned. BMI, waist to hip ratio, fat mass,
and plasma concentration of glucose, serum levels of tri-
glyceride, total cholesterol, and high-density lipoprotein
(HDL) cholesterol were analyzed.
In order to genotype the subjects, the standard salting-
out Proteinase K method was used to extract the germinal
DNA. Both TNF-a promoter polymorphisms were detected
using the RFLP method after amplification of the sequen-
ces by Polymerase Chain Reaction (PCR).
A 107-bp fragment encompassing the -308 variant site
was amplified from genomic DNA by PCR using standard
reagents, technique, and primers (5-AGG CAATAG
GTTTTGAGGGGCCAT-3) and (5-TCCTCCCTGCTCCG
ATTCCG-3) for the -308 variant and (5-ATCTGGA
GGAAGCGGTAGTG-3) and (5-AGAAGACCCCCCTCG
GAACC-3) for the -238 variant allele. To detect -308
variant alleles the PCR product was digested with NcoI at
37C overnight, leaving a 107 bp fragment when the var-
iant was present and products of 87 and 20 bp fragments
for the normal allele visualized on 3% agarose gel. To
detect the -238 variant alleles, the PCR product was
digested with MspI at 37C for an hour, leaving a 152 bp
fragment when the variant was present and products of 133
and 19 bp fragments for the normal allele visualized on 3%
agarose gel.
Statistical analysis
Normality distribution of the data checked by the KS test.
The mean levels of all normally-distributed variants were
tested by ANOVA and the mean levels of all abnormally-
distributed variants were tested by nonparametric Kruskal–
Wallis H test and the data were presented as means ± SD
of the differences. All analyses were conducted using the
SPSS 16 software.
Results
Genotype frequencies in all groups were in accordance
with the Hardy–Weinberg equilibrium. The distribution of
TNF-a genotype for -308 site in under-18 subjects was as
follows: GG (81%), GA (16.6%), and AA (2.4%). In adults
the following results were produced: GG (86.6%), GA
(12.4%), and AA (1%). As for the -238 site in under-18
subjects the results were: GG (80.5%), GA (19.5%), and
AA (0%), and in adults the following results were recor-
ded: GG (79.3%), GA (19.2%), and AA (1.5%). Clinical
and biochemical data of participants, when classified in
accordance to G/A polymorphisms at positions -308 and
-238 of the TNF-a gene promoter, are presented in
Table 1 (-308) and Table 2 (-238). To examine whether
the variant alleles were more common in patients with
obesity, adults were classified in three groups according to
their BMI: BMI \ 25, 25 B BMI \ 30, BMI C 30 and
under-18 subjects were classified in two groups according
to their BMI: under 85th percentile BMI and above 85th
percentile as far as age and sex are concerned—Table 3
(-308) and Table 4 (-238).
Discussion
The purpose of the present study is to determine whether
the G ? A polymorphisms of the TNF-a gene promoter
are associated with obesity and anthropometric parameters
in Cohort Tehran Lipid and Glucose study. There are no
associations between G-308A and G-238A TNF-a pro-
moter polymorphisms and increases in BMI. TNF-a is one
of the cytokines secreted from adipose tissue in obesity; it
can be a candidate gene to inspect obesity and related
diseases. Obesity is a complex metabolic disorder with a
strong genetic component and there are many candidate
genes for obesity and its related phenotypes. Most of these
genes are candidate because their mutations cause rare
genetic syndromes affecting adipocytes differentiation [9].
Recent interest has focused on the role of the TNF-a gene
in insulin resistance and obesity. We therefore examined
the association between the polymorphism of TNF-a and
obesity without metabolic disease. It came as another study
reported an association between this genetic marker and
excessive fat accumulation in women [10].
Moreover, a potential role for the TNF-a locus in
obesity is also supported by a linkage study, which reported
a relationship between the TNF-a locus and various global
measures of adiposity in Pima Indians and European
Caucasians [11, 12]. The functional role of the TNF-a
G-308A polymorphism is currently unclear. However, it is
located within a consensus sequence for the transcription
factor AP-2 in the promoter region of the gene [13].
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The G-308A mutation in the promoter region of TNF-a
acts in vitro as a much stronger transcriptional activator
than the wild-type TNF-a and it is suggested that a higher
transcriptional activity would result in higher TNF-a con-
centrations followed by decreased insulin sensitivity [7].
So this variant could play a role in the development of
obesity and related phenotypes [14]. Interestingly, obesity
is known to be associated with increased levels of TNF-a
mRNA and protein in fat tissue both in humans and in
genetically obese or diabetic rodents [15]. Moreover, a
study has shown that the TNF-a mRNA level in adipose
tissue are significantly correlated with the percentage of
body fat in human obese subjects [5]. A recent study, while
confirming linkage between the TNF-a locus and obesity in
families of French-Canadian origin, has also found a sig-
nificant association between this locus and high blood
pressure [16]. A significant positive correlation between
serum TNF-a concentration and systolic blood pressure has
also been reported among individuals of an isolated native
Canadian population over a wide range of adiposity [17].
An Italian population study suggests that the G-308A
mutation of the TNF-a gene is unlikely to play an impor-
tant role in the development of obesity and its related
metabolic abnormalities such as insulin resistance and
dyslipidemia [18]. As for the G-238A variant, previous
results are also inconsistent. A study of non-diabetic
Table 1 Clinical and biochemical data of subjects when classified in accordance to the genotype of the G/A polymorphisms at positions -308 of
the TNF-a gene promoter
Under 18 Above 18
Trait GG (34) GA (7) AA (1) P GG (175) GA (25) AA (2) P
Age (years) 12.51 ± 2.8 14.21 ± 2.25 10.5 0.240 43.34 ± 15.62 40.96 ± 16.04 51.25 ± 1.76 0.591
Sex (M/F) 17/17 3/4 1/0 0.572 70/105 10/15 1/1 0.960
BMI (kg/m2) 19.73 ± 3.84 19.91 ± 2.07 26.71 0.179 26.65 ± 4.55 27.33 ± 4.82 32.18 ± 2.7 0.196
FBS (mg/dl) 86.45 ± 5.62 87.35 ± 6.51 73.5 0.088 89.00 ± 22.18 90.50 ± 8.66 87.5 ± 7.07 0.865
HOMA 10.1 ± 5.80 9.45 ± 2.87 12.15 0.889 12.13 ± 281.39 12.36 ± 8.83 10.15 ± 0.02 0.683
CHO (mg/dl) 158.57 ± 2.44 169.79 ± 22.38 178.00 0.421 196.57 ± 42.73 197.00 ± 47.91 208.75 ± 44.90 0.925
HDL-C (mg/dl) 44.30 ± 8.60 43 ± 7.34 29 0.208 42.26 ± 9.63 42.76 ± 9.20 31.75 ± 13.78 0.295
LDL-C (mg/dl) 95.96 ± 20.75 109.69 ± 22.87 113.40 0.241 124.53 ± 3.46 118.52 ± 43.83 128.75 ± 40.09 0.723
TG (mg/dl) 94.44 ± 39.00 85.85 ± 21.80 178.50 0.074 128.50 ± 81.07 142.50 ± 154.54 241.25 ± 44.19 0.053
WHR 0.83 ± 0.05 0.82 ± 0.07 0.98 0.053 0.87 ± 0.08 0.86 ± 0.09 0.95 ± 0.06 0.344
SBP (mmHg) 101.31 ± 8.46 104.21 ± 5.12 97 0.579 114.50 ± 17.26 116.50 ± 11.02 131.25 ± 22.27 0.426
DBP (mmHg) 67.22 ± 5.85 71.21 ± 4.87 57.5 0.059 74.36 ± 8.09 75.34 ± 8.98 83 ± 16.26 0.303
Table 2 Clinical and biochemical data subjects when classified in accordance to the genotype of the G/A polymorphisms at positions -238 of
the TNF-a gene promoter
Under 18 Above 18
Trait GG (33) GA (8) AA (0) P GG (175) GA (38) AA (3) P
Age (years) 13.24 ± 2.96 12.62 ± 2.21 – 0.585 42.18 ± 15.01 39.93 ± 16.50 42.50 ± 21.07 0.585
Sex (M/F) 13/20 4/4 – 0.589 97/60 17/21  0.745
BMI (kg/m2) 20.12 ± 3.58 19.08 ± 2.88 – 0.454 26.40 ± 4.37 26.84 ± 4.71 23.37 ± 3.12 0.415
FBS (mg/dl) 87.63 ± 6.24 84.50 ± 6.83 – 0.218 89 ± 41.62 87.25 ± 23.13 89 ± 13.47 0.766
HOMA 10.79 ± 6.42 10.28 ± 3.03 – 0.828 12.13 ± 8.85 10.15 ± 9.18 10.19 ± 1.04 0.158
CHO (mg/dl) 162.18 ± 23.99 146.38 ± 26.83 – 0.110 199.08 ± 40.46 183.78 ± 37.69 214.17 ± 92.59 0.090
HDL-C (mg/dl) 43.83 ± 7.62 43.12 ± 7.80 – 0.816 42.85 ± 9.03 42.18 ± 10.25 41.66 ± 4.19 0.904
LDL-C (mg/dl) 100.08 ± 19.52 87.30 ± 27.62 – 0.134 125.92 ± 34.11 112.62 ± 32.22 148.07 ± 83.89 0.052
TG (mg/dl) 94.30 ± 37.85 80 ± 30.23 – 0.328 123.00 ± 97.55 145.25 ± 57.70 103.50 ± 56.73 0.519
WHR 0.82 ± 0.04 0.8 ± 0.11 – 0.451 0.87 ± 0.08 0.87 ± 0.1 0.83 ± 0.11 0.780
SBP (mmHg) 100.42 ± 8.51 104.56 ± 7.72 – 0.217 115.14 ± 15.20 115.86 ± 15.04 103 ± 21.65 0.757
DBP (mmHg) 66.33 ± 5.17 70.12 ± 6.28 – 0.082 73.88 ± 7.80 75.46 ± 7.71 70.83 ± 6.65 0.407
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relatives and control subjects in Britain showed that the
-238 variant was associated with increased insulin sensi-
tivity as estimated by two independent methods [19]. A
recent meta-analysis (2,106 cases and 2,920 controls) of
the rs361525 (G-238A) variant has not detected a signifi-
cant association with type 2 diabetes [20], nor has the study
of Caucasian and African American subjects [21].
Be0ne0dicte Fontaine-Bisson and co-workers suggest that
the -238G ? A and -308G ? A polymorphisms of
TNF-a alter circulating free fatty acids and insulin
resistance in obese subjects with type 2 diabetes mellitus
[22].
Table 3 Clinical and biochemical data of subjects when classified in accordance to BMI for polymorphisms at positions -308 of the TNF-a
gene promoter
Under 18 Above 18
Trait Grade 1 Grade 2 P Grade 1 Grade 2 Grade 3 P
BMI \ 85% BMI [ 85% BMI \ 25 25 B BMI \ 30 BMI C 30
(n = 26) (n = 16) (n = 75) (n = 81) (n = 46)
GG 21(80.8%) 13(81.2%) – 67(89.3%) 71(87.7%) 37(80.4%) –
GA 5(19.2%) 2(12.51%) – 8(10.7%) 10(12.3%) 7(15.2%) –
AA – 1(6.2%) – – – 2(4.3%) –
Age (years) 12.88 ± 2.76 12.53 ± 2.81 0.692 36.37 ± 16.65 45.56 ± 14.36 49.85 ± 11.46 0.000
BMI (kg/m2) 17.64 ± 2.03 2.60 ± 23.63 0.000 22.27 ± 1.93 27.49 ± 1.42 32.90 ± 3.37 0.000
FBS (mg/dl) 86.34 ± 6.21 86.34 ± 6.21 0.948 87 ± 21.07 91 ± 16.66 91.50 ± 26.02 0.001
HOMA 9.94 ± 4.80 10.22 ± 6.27 0.870 12.34 ± 10.18 12.47 ± 413.40 10.31 ± 5.78 0.071
CHO (mg/dl) 155.9 ± 22.13 169.03 ± 25.49 0.086 181.50 ± 42.11 201.32 ± 43.50 213.51 ± 36.66 0.000
HDL-C (mg/dl) 43.19 ± 7.74 44.59 ± 9.93 0.612 42.53 ± 9.18 36.98 ± 8.37 45.62 ± 11.34 0.005
LDL-C (mg/dl) 96.12 ± 19.71 102.79 ± 23.82 0.332 113.77 ± 36.47 125.82 ± 34.53 136.71 ± 32.79 0.002
TG (mg/dl) 86.78 ± 27.92 108.37 ± 49.33 0.077 108 ± 67.10 154.50 ± 117.21 135.25 ± 70.22 0.000
WHR 0.81 ± 0.05 0.86 ± 0.06 0.008 0.83 ± 0.07 0.89 ± 0.08 0.9 ± 0.07 0.000
SBP (mmHg) 100.78 ± 8.14 103.15 ± 7.65 0.355 111.50 ± 11.78 116 ± 18 119 ± 17.75 0.000
DBP (mmHg) 67.51 ± 6.36 67.87 ± 5.52 0.854 71.57 ± 7.23 75.51 ± 8.11 77.79 ± 8.69 0.000
Table 4 Clinical and biochemical data of subjects when classified in accordance to BMI for polymorphisms at positions -238 of the TNF-a
gene promoter
Under 18 Above 18
Trait Grade 1 Grade 2 P Grade 1 Grade 2 Grade 3 P
BMI \ 85% BMI [ 85% BMI \ 25 25 B BMI \ 30 BMI C 30
(n = 26) (n = 16) (n = 75( (n = 81) (n = 46)
GG 21(80.8%) 13(80%) – 65(81.2%) 60(77.9%) 32(78%) –
GA 5(19.2%) 2(20%) – 13(16.2%) 16(20.8%) 9(22%) –
AA – – – 2(2.5%) 1(1.3%) – –
Age (years) 13.50 ± 2.75 12.46 ± 2.90 0.264 38 ± 16.61 42.42 ± 13.85 50.24 ± 12.16 0.000
BMI (kg/m2) 18.05 ± 2.28 23.15 ± 2.63 0.000 22.27 ± 1.89 27.50 ± 1.43 32.57 ± 3.18 0.000
FBS (mg/dl) 86.86 ± 7.21 87.30 ± 4.88 0.837 87 ± 54 89 ± 26.03 92 ± 15.04 0.011
HOMA 10.97 ± 5.69 10.21 ± 6.39 0.696 11.32 ± 8.92 12.14 ± 9.73 10.44 ± 6.73 0.385
CHO (mg/dl) 154.36 ± 22.76 167.30 ± 27.41 0.112 186.30 ± 41.59 200.50 ± 42.15 208.26 ± 34.04 0.011
HDL-C (mg/dl) 42.19 ± 6.31 46.30 ± 8.99 0.094 43.35 ± 8.64 40.66 ± 8.26 45.30 ± 11.39 0.023
LDL-C (mg/dl) 95.35 ± 19.41 101.44 ± 25.09 0.391 117.18 ± 36.66 126.27 ± 34.73 131.60 ± 30.38 0.071
TG (mg/dl) 87.8 ± 29.78 97.93 ± 46.60 0.4 110.50 ± 69.11 144.50 ± 111.46 135 ± 69.81 0.000
WHR 0.80 ± 0.06 0.85 ± 0.05 0.012 0.83 ± 0.08 0.89 ± 0.08 0.89 ± 0.08 0.000
SBP (mmHg) 99.4 ± 8.42 104.4 ± 7.71 0.067 111.75 ± 12.67 115 ± 14.84 118.5 ± 17.34 0.001
DBP (mmHg) 66.94 ± 5.68 67.30 ± 5.45 0.845 72.11 ± 7.22 74.13 ± 7.54 78.09 ± 7.87 0.000
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